DYNHealthcare · BiotechnologyThe 17 Wall Street analysts covering Dyne Therapeutics, Inc. hold a median 12-month price target of $36 — +94.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Dyne Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (72): The shares have been drifting up relative to others.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DYN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +94.1% from it.
Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Oppenheimer | Downgrade | Perform | $40 → $15 |
| 30 Sept 2026 | Chardan Capital | Maintains | Buy | — |
| 30 Sept 2026 | Chardan Capital | Maintains | Buy | $38 |
| 30 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $50 → $32 |
| 29 Sept 2026 | Piper Sandler | Reiterates | Overweight | — |
| 29 Sept 2026 | Piper Sandler | Reiterates | Overweight | $47 |
| 9 Sept 2026 | Baird | Maintains | Outperform | — |
| 9 Sept 2026 | Baird | Maintains | Outperform | $30 → $26 |
| 9 Sept 2026 | JP Morgan | Downgrade | Underweight | — |
| 9 Sept 2026 | JP Morgan | Downgrade | Underweight | $17 → $10 |
| 9 Sept 2026 | Morgan Stanley | Maintains | Overweight | — |
| 9 Sept 2026 | Morgan Stanley | Maintains | Overweight | $45 → $36 |
| 9 Sept 2026 | RBC Capital | Maintains | Outperform | — |
| 9 Sept 2026 | RBC Capital | Maintains | Outperform | $35 → $30 |
| 31 July 2026 | Morgan Stanley | Maintains | Overweight | $47 → $45 |
| 31 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 30 July 2026 | RBC Capital | Maintains | Outperform | $30 → $35 |
| 30 July 2026 | RBC Capital | Maintains | Outperform | — |
| 23 July 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DYN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Dyne Therapeutics, Inc. returned −13.8% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 22% of US stocks
Cheaper than 80% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 15% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Dyne Therapeutics, Inc. has a market value of $3.4B and an enterprise value of $2.6B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$519.4M.
Diluted earnings per share, trailing twelve months: $−3.33.
Free cash flow in the twelve months to 30 June 2026: −$499.2M.
Trailing P/E: −5.2×; forward P/E: −5.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Dyne Therapeutics, Inc. employs 289 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Dyne Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Dyne Therapeutics announced inducement equity awards for 16 newly hired employees. The awards were made in connection with their acceptance of employment and under Nasdaq Listing Rule 5635(c)(4).
Why it matters — The grants provide information about equity awards associated with recent hiring at Dyne.
Dyne Therapeutics announced additional one-year clinical data from the Phase 1/2 ACHIEVE trial of Z-Basivarsen (DYNE-101) for myotonic dystrophy type 1. Data from a pooled dose group of participants in the multiple ascending dose portion showed functional improvement versus baseline, versus placebo, and versus a matched natural history cohort across multiple measures at 12 months.
Why it matters — This provides longer-term evidence of functional benefit for DYNE-101, a key pipeline candidate for a condition with limited treatment options.
Dyne Therapeutics announced that it granted inducement equity awards to 14 newly hired employees, made as an inducement material to their acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — A Dyne Therapeutics watcher would care because this reflects the company's ongoing recruitment of new talent through equity-based hiring incentives, a standard corporate practice under Nasdaq rules.
Dyne Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The presentation covered the company's updates at the industry conference.
Why it matters — A DYN watcher would care because the conference presentation offers investors insight into the company's positioning and updates as communicated by management.
Dyne Therapeutics' stock fell 16% after Novartis' DM1 (HARBOR) trial failure raised platform-wide clinical risk concerns about RNA-targeting therapies. The item keeps a Buy rating on DYN but notes that its lead asset, z-rostudirsen, now faces regulatory and confirmatory risks with more uncertain long-term value due to functional outcome concerns.
Why it matters — A DYN watcher would care because the Novartis trial failure casts doubt on the class-wide RNA-targeting approach, directly affecting the prospects and perceived risk of DYN's own DM1 and DMD programs.
The 17 Wall Street analysts covering Dyne Therapeutics, Inc. have a median 12-month price target of $36, with estimates ranging from $10 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Dyne Therapeutics, Inc., 15 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Dyne Therapeutics, Inc. 33 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Dyne Therapeutics, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (72 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +94.1% from the last close, and Ticker Nerd's factor model ranks Dyne Therapeutics, Inc. 33 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Dyne Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DYN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $50 over the next 12 months.
Dyne Therapeutics, Inc. returned -13.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Dyne Therapeutics announced inducement equity awards for 16 newly hired employees. The awards were made in connection with their acceptance of employment and under Nasdaq Listing Rule 5635(c)(4).
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases. Dyne Therapeutics advances a pipeline of investigational medicines designed to deliver treatment directly to muscle tissue and, in some programs, the central nervous system through its proprietary FORCE platform. Its current programs address conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease, along with other rare skeletal, cardiac, and metabolic muscle disorders. The company’s work centers on disease-modifying approaches aimed at the underlying genetic causes of these conditions, positioning it as a specialized player in rare disease drug development. Dyne Therapeutics is headquartered in Waltham, Massachusetts.
CEO Mr. John G. Cox M.B.A. · 289 employees · United States · https://www.dyne-tx.com
